Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT ID: NCT00703313

Last Updated: 2009-02-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31

Brief Summary

The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

2

described in intervention

Group Type: ACTIVE_COMPARATOR

0.5% moxifloxacin hydrochloride ophthalmic solution

Intervention Type: DRUG

1 drop instilled at each visit

3

described in intervention

Group Type: ACTIVE_COMPARATOR

0.3% gatifloxacin ophthalmic solution

Intervention Type: DRUG

1 drop instilled at each visit

1

described in intervention

Group Type: ACTIVE_COMPARATOR

1.5% levofloxacin ophthalmic solution

Intervention Type: DRUG

1 drop instilled at each visit

Interventions

1.5% levofloxacin ophthalmic solution

1 drop instilled at each visit

Intervention Type: DRUG

0.5% moxifloxacin hydrochloride ophthalmic solution

1 drop instilled at each visit

Intervention Type: DRUG

0.3% gatifloxacin ophthalmic solution

1 drop instilled at each visit

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Be willing and able to provide written informed consent and HIPAA indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
• Be willing and able to follow all instructions and attend all study visits
• If female and of childbearing potential, not be pregnant, nursing or planning a pregnancy and agree to submit to a pregnancy test. The result of the test must be negative and female subjects of childbearing potential must also agree to use an acceptable method of contraception for the duration of the study (acceptable method of contraception includes oral, implantable, transdermal, or injectible contraceptives, spermicide with barrier, IUD, or surgical sterilization of partner)

Exclusion Criteria

• Have a known allergy and/or sensitivity to the test article(s) or its components or any therapies associated with the study
• Have active signs or symptoms of any clinically significant ocular disorder (other than refractive disorders)
• Have a history of dry eye syndrome
• Use disallowed medications (systemic or topical) (i.e. any fluoroquinolone anti-infective agents or any topical ophthalmic products) during the appropriate pre-study washout period and during the study.
• Be a contact lens wearer who is unwilling to forego contact lens wear within 3 days prior to the start of the study and for the duration of the study
• Have had any ocular surgical intervention 12 months prior to the study or anticipate having ocular surgery during the study
• Be pregnant or nursing women; or women who have a positive urine pregnancy test at screening or women of childbearing potential who refuse to use an adequate hormonal or mechanical means of birth control
• Be concurrently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of entry into this study
• Employees of the investigator or study center, with direct involvement in th proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Santen Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

VISTAKON Pharmaceuticals

Locations

Vistakon

Jacksonville, Florida, United States

Countries

United States

Other Identifiers

VPH0108

Identifier Type: -

Identifier Source: org_study_id